Gastrointestinal stromal tumor secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Gastrointestinal stromal tumor}}
{{Gastrointestinal stromal tumor}}
==Overview==
==Overview==
There are no established measures for the secondary prevention of [disease name].


OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].


GIST on medical therapy tender to have a recurrent course and must be evaluated on a periodic basis.Effective measures for the secondary prevention of gastrointestinal stromal tumors include regular follow ups including physical examination with laboratory and imaging evaluations.
==Secondary Prevention==
==Secondary Prevention==
Effective measures for the secondary prevention of gastrointestinal stromal tumor include:
Effective measures for the secondary prevention of gastrointestinal stromal tumors (GIST) include:
*Regular follow ups including physical examination with laboratory and imaging evaluations.
*Regular follow ups including physical examination with laboratory and imaging evaluations.
**GISTs are known to present with locally recurrent and distant metastasis and thus periodic evaluation through a CT scan should be done for early detection of recurrent disease. However, there is no consensus on the time interval between assessment.
**GISTs are known to present with locally recurrent and distant metastasis and thus periodic evaluation through a CT scan should be done for early detection of recurrent disease. However, there is no consensus on the time interval between assessment.

Revision as of 21:26, 12 December 2017

Gastrointestinal stromal tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Gastrointestinal stromal tumor from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gastrointestinal stromal tumor secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gastrointestinal stromal tumor secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gastrointestinal stromal tumor secondary prevention

CDC on Gastrointestinal stromal tumor secondary prevention

Gastrointestinal stromal tumor secondary prevention in the news

Blogs on Gastrointestinal stromal tumor secondary prevention

Directions to Hospitals Treating Gastrointestinal stromal tumor

Risk calculators and risk factors for Gastrointestinal stromal tumor secondary prevention

Overview

GIST on medical therapy tender to have a recurrent course and must be evaluated on a periodic basis.Effective measures for the secondary prevention of gastrointestinal stromal tumors include regular follow ups including physical examination with laboratory and imaging evaluations.

Secondary Prevention

Effective measures for the secondary prevention of gastrointestinal stromal tumors (GIST) include:

  • Regular follow ups including physical examination with laboratory and imaging evaluations.
    • GISTs are known to present with locally recurrent and distant metastasis and thus periodic evaluation through a CT scan should be done for early detection of recurrent disease. However, there is no consensus on the time interval between assessment.
    • Patients with indeterminate or inaccessible lesions can be evaluated with PET scans to identify malignant lesions from benign lesions.
      • A positron emission tomography (PET) scanning can also be used to determine response to therapy and can identify active tumor from necrotic and inactive scar tissue. This is particularly helpful in patients receiving tyrosine kinase inhibitor therapy for incompletely resected, recurrent, or metastatic disease.

References


Template:WikiDoc Sources